The COVID-19 pandemic, heart and cardiovascular diseases: What we have learned

被引:2
|
作者
Piatek, Zuzanna [1 ]
Gac, Pawel [2 ]
Poreba, Malgorzata [3 ]
机构
[1] Wroclaw Med Univ, Vide Cor Meum Students Sci Circle Div Pathophysio, Wroclaw, Poland
[2] Wroclaw Med Univ, Div & Dept Hyg, Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Physiol & Pathophysiol, Div Pathophysiol, Wroclaw, Poland
关键词
cardiovascular diseases; COVID-19; SARS-CoV-2; RENIN-ANGIOTENSIN SYSTEM; CLINICAL CHARACTERISTICS; CARDIAC-TAMPONADE; MYOCARDITIS; INFLAMMATION; PATIENT; ACE2; SARS;
D O I
10.17219/dmp/133153
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
In 2020, the coronavirus disease 2019 (COVID-19) pandemic overwhelmed the world, temporarily paralyzing healthcare and economic systems. Until now, we have learned a lot about the symptoms, pathophysiology, and complications of the disease as well as about the laboratory findings concerning the disease, and we are rapidly acquiring new data on the influence of COVID-19 on other aspects of human health beside its effects on the respiratory system. Patients with co-existing cardiovascular diseases (CVD) are more frequently hospitalized, more likely to be treated in an intensive care unit (ICU) and have poorer prognoses. In this article, we discuss the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on CVD, starting from the mechanisms connected with the renin-angiotensin-aldosterone system (RAAS) and the angiotensin-converting enzyme 2 (ACE2) receptors, and then describing the main pathologies in the heart and vessels detected in patients with COVID-19. Additionally, we comment on the problem of acute coronary syndrome (ACS), which may be triggered by viral infection. Finally, we discuss how, in some countries, the pandemic has changed treatment patterns, lowering the rate of invasive diagnostics and even falsely reducing the prevalence of CVD as a result of patients' fear of being admitted to hospital.
引用
收藏
页码:219 / 227
页数:9
相关论文
共 50 条
  • [31] COVID-19 and Gynecologic Oncology: What Have We Learned?
    Leibold, Aurora
    Papatla, Katyayani
    Zeligs, Kristen P.
    Blank, Stephanie, V
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2021, 22 (12)
  • [32] COVID-19 and Gynecologic Oncology: What Have We Learned?
    Aurora Leibold
    Katyayani Papatla
    Kristen P. Zeligs
    Stephanie V. Blank
    Current Treatment Options in Oncology, 2021, 22
  • [33] COVID-19 isolation strategies: What have we learned
    Al-Tawfiq, Jaffar A.
    Memish, Ziad A.
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2022, 49
  • [34] The COVID-19 challenge. What have we learned?
    Ceccato, Adrian
    Luna, Carlos M.
    Artigas, Antonio
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2022, 48 (05)
  • [35] COVID-19 and cancer care: What have we learned?
    Nelson, Bryn
    Kaminsky, David B.
    CANCER CYTOPATHOLOGY, 2020, 128 (12) : 879 - 880
  • [36] What have we learned from the COVID-19 plague?
    Plotkin, Stanley A.
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (611)
  • [37] Physical Education and COVID-19: what have we learned?
    Varea, Valeria
    Riccetti, Ana
    Gonzalez-Calvo, Gustavo
    Siracusa, Marcela
    Garcia-Monge, Alfonso
    CURRICULUM STUDIES IN HEALTH AND PHYSICAL EDUCATION, 2024, 15 (03) : 340 - 357
  • [38] What have we learned ventilating COVID-19 patients?
    Uriel Trahtemberg
    Arthur S. Slutsky
    Jesús Villar
    Intensive Care Medicine, 2020, 46 : 2458 - 2460
  • [39] Severe COVID-19: what have we learned with the immunopathogenesis?
    Bordallo, Bruno
    Bellas, Mozart
    Cortez, Arthur Fernandes
    Vieira, Matheus
    Pinheiro, Marcelo
    ADVANCES IN RHEUMATOLOGY, 2020, 60 (01)
  • [40] Severe COVID-19: what have we learned with the immunopathogenesis?
    Bruno Bordallo
    Mozart Bellas
    Arthur Fernandes Cortez
    Matheus Vieira
    Marcelo Pinheiro
    Advances in Rheumatology, 60